ARDX
NASDAQ HealthcareArdelyx, Inc. - Common Stock
Biotechnology
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $5.12 |
|---|---|
| Volume | 2,435,269 |
| Market Cap | 1.27B |
| Beta | 0.600 |
| RSI (14-Day) | 25.6 Oversold |
| 200-Day MA | $6.04 |
| 50-Day MA | $5.87 |
| 52-Week High | $8.40 |
| 52-Week Low | $4.08 |
| Forward P/E | 9.95 |
| Price / Book | 8.51 |
๐ฏ Investment Strategy Scores
ARDX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (93/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ARDX in your text
Paste any article, transcript, or post โ the tool will extract ARDX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.